J&J to buy heart failure devicemaker

Johnson & Johnson plans to scoop V-Wave, a heart failure devicemaker, for up to $1.7 billion by the end of 2024. 

Advertisement

The acquisition will have a $600 million upfront payment and up to another $1.1 billion pending regulatory and commercial milestones, according to an Aug. 20 J&J news release. 

V-Wave is a privately held company that targets heart failure with reduced ejection fraction, and its Ventura Interatrial Shunt addressed an unmet need for about 800,000 patients, the release said. 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.